Logo image
Antioxidant use in Friedreich ataxia
Journal article   Peer reviewed

Antioxidant use in Friedreich ataxia

Lauren Myers, Jennifer M Farmer, Robert B Wilson, Lisa Friedman, Amy Tsou, Susan L Perlman, Sub H Subramony, Christopher M Gomez, Tetsuo Ashizawa, George R Wilmot, …
Journal of the neurological sciences, Vol.267(1), pp.174-176
2008
DOI: 10.1016/j.jns.2007.10.008
PMCID: PMC2279016
PMID: 17988688
url
http://doi.org/10.1016/j.jns.2007.10.008View
Open Access

Abstract

Many antioxidants have been suggested as potential treatments for Friedreich ataxia, but have not been tested in clinical trials. We found that a majority of patients in our cohort already use such antioxidants, including idebenone, which is not available at a pharmaceutical grade in the United States. Younger age, cardiomyopathy and shorter GAA repeat length were independent predictors of idebenone use, but no factors predicted use of other antioxidants. This confirms that non-prescription antioxidant use represents a major confounder to formal trials of existing and novel agents for Friedreich ataxia.
Ataxia Cerebellum Idebenone Clinical trial

Details

Metrics

Logo image